Antiviral Intervention of COVID-19: Linkage of Disease Severity with Genetic Markers FGB (rs1800790), NOS3 (rs2070744) and TMPRSS2 (rs12329760)

The purpose of this study was to investigate polymorphic variants of the genes FGB (rs1800790), NOS3 (rs2070744) and TMPRSS2 (rs12329760) in patients with coronavirus infection and to determine their role in the development of clinical forms of COVID-19 on the background of antiviral therapy. Real-time polymerase chain reaction (RT-PCR) was used to genotype the polymorphism of the selected genes. GS-5734 (Remdesivir) was prescribed as the basic antiviral drug. Binary logistic regression confirmed a low probability of developing COVID-19 in carriers of the mutational A-allele of the FGB gene. The highest probability of developing moderate and severe clinical forms of COVID-19 among residents of Central Ukraine was found in carriers of the G-allele (especially the GG genotype) of the FGB gene (rs1800790) and the T-allele of the TMPRSS2 gene (rs12329760). The administration of the antiviral drug GS-5734 (Remdesivir) and anti-inflammatory therapy reduces the blood level of TMPRSS2 in moderate and IL-6 in severe COVID-19. The proposed treatment does not significantly affect the concentration of endothelin-1, but a decrease in procalcitonin associated with additional antibacterial use was observed, especially in severe COVID-19.